Influenza Vaccine Immune Responses Across Age Groups and Vaccine Types

Engin Berber's dataset contains serological measurements from a three-season study of influenza vaccine effectiveness. The data includes hemagglutination inhibition (HAI) titers from 1,328 participants aged 9–89 years who received one of six vaccine types between 2022–2025. It tracks seroprotection and seroconversion rates before and after vaccination, analyzing outcomes by age group and vaccine platform.

Use Cases

• Compare antibody titers across different vaccine formulations based on the six vaccine types mentioned.
• Analyze age-related differences in immune response based on participant ages ranging from 9 to 89 years.
• Study the impact of repeated annual vaccination on antibody boosting based on the three-season study design.
• Evaluate seroconversion and seroprotection rates against historical and current strains based on HAI activity testing.

Strengths

• Includes data from 1,328 participants, providing a substantial sample size.
• Covers three consecutive seasons (2022–2025), allowing longitudinal analysis.
• Compares six distinct vaccine types (Fluzone SD/HD, Fluad, Flucelvax, Flublok, Flumist).
• Contains pre- and post-vaccination (day 28) serum measurements for temporal analysis.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is 292.5 KB, indicating a limited scope of data.

Provenance

Source

Engin Berber

Collection Method

Serum samples collected from participants were tested for hemagglutination inhibition (HAI) activity.

Time Range

2022–2025

Freshness

Last updated 2026-04-16 17:37:39; freshness should be verified.